338 Spear St Unit 11F
San Francisco, CA 94105
Encellin is developing an ultra thin-film implantable cell delivery system. Encellin’s system will enclose and replace the cells responsible for making insulin, enabling patients to have better control over their blood glucose levels. Encelin’s initial focus is on addressing the severe hypoglycemic episodes (SHE) of type 1 diabetic (T1D) patients.